LL-37 Peptide: What It Is, How It Works, and What the Research Shows

LL-37 is a 37-amino-acid human antimicrobial peptide derived from hCAP-18. It can disrupt bacterial membranes, recruit immune cells, and support wound-healing signals. LL-37 is not FDA-approved for any indication, and U.S. patient access requires a prescription through a licensed clinician and 503A compounding pharmacy. [1][2][9]

What is LL-37 peptide?

LL-37 is the active 37-amino-acid piece of hCAP-18, also called human cathelicidin antimicrobial protein. hCAP-18 is encoded by the CAMP gene and belongs to the cathelicidin family, a group of peptides involved in early immune defense. In the body, LL-37 is found in immune cells and barrier tissues like skin, lungs, and the gut. [1][2]

Where LL-37 comes from in the body

The body first makes a larger protein, hCAP-18. Enzymes then cut this protein into smaller active pieces. One important enzyme is proteinase 3, which can cleave hCAP-18 to release LL-37 from immune cells called neutrophils. [2]

How LL-37 is made from hCAP-18

LL-37 is named for its first two amino acids, leucine and leucine, and its 37-amino-acid length. Its structure lets it interact with charged microbial membranes. That helps explain why it has been studied as an antimicrobial peptide, but that does not mean it is proven or approved as an infection treatment. [1][2]

What does LL-37 do?

LL-37 has three main research areas: antimicrobial activity, immune signaling, and wound repair. In lab and animal studies, it can damage some bacterial membranes, attract immune cells, and affect skin-cell movement. These same immune effects may also create risks, especially in inflammatory or autoimmune conditions. [1][3][4]

Direct antimicrobial action

LL-37 can interact with microbial membranes and has shown activity against some bacteria in laboratory studies. It has also been studied for antibiofilm effects, meaning effects on bacterial communities that stick to surfaces. These findings are early-stage and do not prove that LL-37 safely treats infections in people. [1][11]

Immune cell recruitment via FPR2/FPRL1

LL-37 can act as a signaling molecule. One study found that LL-37 attracts human immune cells through formyl peptide receptor-like 1, also called FPRL1 or FPR2. This may help explain its role in early immune response, but it also means LL-37 can influence inflammation. [3]

Wound healing and angiogenesis

LL-37 has been studied in wound healing because it may support re-epithelialization, the process where skin cells move to cover a wound. It has also been shown to promote blood-vessel growth signals in research models. Benefits are not established for routine patient care, and risks include local irritation, excess inflammation, or unknown effects in chronic disease. [4][5]

What is LL-37 being studied for?

LL-37 is being studied for wound repair, antimicrobial defense, mucosal immunity, and inflammatory signaling. It is not FDA-approved for these uses. Research is strongest for biology and early models, while human data remain limited, so side effects and contraindications are not fully defined. [4][5][9]

Chronic wounds and skin ulcers

In skin research, LL-37 has been linked with keratinocyte movement and wound closure signals. A human wound study found LL-37 expression in healing skin and suggested a role in re-epithelialization. This does not prove that compounded LL-37 improves chronic wounds, and people with ulcers need medical care to check for infection, blood-flow problems, and diabetes-related risks. [4]

Antimicrobial and antibiofilm research

LL-37 is often discussed as an antimicrobial peptide because it can disrupt some bacteria and influence biofilms in research settings. However, antimicrobial activity in a dish is not the same as safe treatment in the body. Possible risks include tissue irritation, changes in immune signaling, and treatment delays if a serious infection is not properly evaluated. [1][11]

Mucosal and respiratory immunity

LL-37 is present at barrier sites, including mucosal surfaces. Researchers study it because these tissues need fast defense against microbes. Still, LL-37 is not an approved respiratory, gut, sinus, or immune treatment, and its inflammatory effects may not be safe for every person. [1][12]

What are the potential side effects and risks of LL-37?

LL-37 side effects are not well mapped in large human trials. Based on its biology, possible risks include injection-site irritation, redness, swelling, immune activation, and inflammation. Because LL-37 can affect immune pathways, extra caution is important for people with autoimmune disease, active infection, cancer, pregnancy, breastfeeding, or immune-suppressing medicines. [3][6][7]

Cytotoxicity at higher concentrations

LL-37 can harm some mammalian cells at higher concentrations in lab settings. That is one reason patient use should not be treated like a simple supplement. There is no FDA-approved dosing plan, and this article does not provide dosing instructions. [1][11]

Links to autoimmune and inflammatory conditions

LL-37 has been linked to inflammatory disease pathways. In psoriasis research, LL-37 can form complexes with self-DNA and activate immune cells. In lupus research, similar immune-complex activity has been described. These findings do not mean LL-37 causes every case of these diseases, but they raise safety questions for people with autoimmune risk. [6][7]

Unknowns from limited human data

Because LL-37 is not an FDA-approved drug, there is no FDA label that defines approved uses, standard dosing, common adverse reactions, or contraindications. Safety may depend on formulation quality, route, health history, and other medicines. A licensed clinician should review these factors before any prescription is considered. [9][10]

What diseases are linked to LL-37 dysregulation?

LL-37 dysregulation means LL-37 activity may be too high, too low, or present in the wrong tissue context. It has been studied in psoriasis, lupus, rheumatoid arthritis, atherosclerosis, and neuroinflammation. These links are not proof that taking LL-37 helps these diseases; in some settings, LL-37 may worsen inflammation. [6][7][12]

Psoriasis and atopic dermatitis

In psoriasis, LL-37 has been shown to form immune-activating complexes with self-DNA, which may contribute to inflammation. In atopic dermatitis, antimicrobial peptide patterns can differ from healthy skin. These findings support a role for LL-37 in skin immunity, but they also show why self-directed use can be risky. [6][12]

Lupus and rheumatoid arthritis

Systemic lupus erythematosus, or SLE, involves immune reactions against the body’s own tissues. Research has shown that LL-37 can bind self-DNA and support immune activation in lupus pathways. LL-37 has also been studied in rheumatoid arthritis inflammation, but it is not an approved treatment for autoimmune disease. [7][12]

Atherosclerosis and neuroinflammation

LL-37 has been investigated in cardiovascular and brain-inflammation research because innate immune signals can affect blood vessels and nervous-system tissue. These areas remain complex and early. Any possible benefit must be weighed against inflammation risk and the lack of approved human indications. [12][13]

Is LL-37 FDA-approved?

LL-37 is not FDA-approved for infection, wound healing, autoimmune disease, longevity, gut health, or any other human indication. That means there is no FDA-reviewed LL-37 drug label proving safety and effectiveness for a specific use. Any clinical discussion should be framed as investigational and individualized. [9]

Current regulatory status

In the U.S., compounded drugs are not FDA-approved, even when they are made under federal and state rules. Section 503A of the Federal Food, Drug, and Cosmetic Act allows certain patient-specific compounded prescriptions when legal requirements are met. This is different from an FDA-approved manufactured drug. [10]

503A Category 1 bulk substance list

Some nominated bulk drug substances are placed in FDA’s 503A Category 1 while the agency evaluates whether they should be included on the 503A Bulks List. LL-37 is currently under FDA review, with PCAC scheduled to discuss inclusion on the 503A Bulks List on July 23-24, 2026; this is not an approval decision or a guarantee of future availability. [9]

How do you get LL-37 peptide legally?

Compounded LL-37 should only be obtained with a prescription from a licensed clinician and dispensed by a licensed 503A pharmacy when federal and state requirements are met. A 503A pharmacy prepares a patient-specific compounded medication; compounded drugs are not FDA-approved and should be used only with clinical oversight. [10]

Prescription and clinical evaluation

A clinical evaluation should review the reason LL-37 is being considered, medical history, allergies, immune conditions, current medicines, pregnancy status, and infection risk. This is especially important because LL-37 affects immune signaling and does not have an FDA-approved label with standard contraindications. [3][6][7]

Compounded LL-37 through a 503A pharmacy

If a clinician determines that a compounded prescription is appropriate, the pharmacy should follow applicable 503A rules and quality standards. Patients should avoid research-only products, gray-market vials, or products sold without a prescription, because identity, potency, sterility, and storage may be uncertain. [10]

Getting LL-37 through Chia

Chia is one telehealth option where a licensed clinician can review eligibility for compounded longevity peptides, including whether LL-37 is appropriate under current law and pharmacy availability. The right path may also be an in-person clinician, specialist, or local compounding pharmacy, depending on your health history and state rules.

How does LL-37 compare to other peptides?

LL-37 is mainly discussed as an antimicrobial and immune-signaling peptide. BPC-157 is mainly discussed in tissue-repair research, while thymosin alpha-1 is studied for immune modulation. None of these peptides should be used as a substitute for medical care, and FDA status differs by product and use. [1][14][15]

LL-37 vs BPC-157

LL-37 and BPC-157 are sometimes compared because both appear in wound and tissue-repair discussions. The difference is that LL-37 has strong innate-immune and antimicrobial biology, while BPC-157 research focuses more on tissue-protection and repair pathways. Both lack FDA-approved human indications, and both need clinician oversight because benefits, side effects, and contraindications are not fully defined. [1][14]

LL-37 vs thymosin alpha-1

LL-37 can act directly on microbial membranes and immune-cell signaling. Thymosin alpha-1 is studied more as an immune-modulating peptide. Combining or substituting immune-active peptides without medical guidance may raise risk, especially in autoimmune disease, transplant medicine, cancer care, pregnancy, or active infection. [3][15]

What peptides stack well with LL-37?

LL-37 stacks are sometimes discussed in clinical and research practice, but there are no combination-specific FDA-approved protocols. Any pairing should be viewed as investigational, not a recommendation. Safety review matters because immune and wound-healing signals can overlap. [9][10]

• LL-37 + BPC-157: This pairing is discussed around tissue repair because LL-37 is linked to antimicrobial and re-epithelialization signals, while BPC-157 is studied in tissue-injury models. The safety caveat is that combination trials are lacking, both are not FDA-approved for human indications, and inflammation or product-quality risks must be reviewed by a clinician. [4][14]
• LL-37 + thymosin alpha-1: This pairing is discussed around immune support because both can affect immune signaling in different ways. The safety caveat is that immune-active peptides may be inappropriate in autoimmune disease, transplant history, cancer care, pregnancy, or active infection without specialist input. [3][15]
• LL-37 + GHK-Cu: This pairing is discussed in skin and wound-healing contexts because LL-37 is linked to re-epithelialization and GHK-Cu is studied in skin remodeling. The safety caveat is that there are no strong human trials proving the combination is safe or effective, and topical versus injectable use changes risk. [4][16]

Frequently asked questions about LL-37

Keep reading

Longevity Peptides

BPC-157 Side Effects: What the Evidence Actually Shows

Longevity Peptides

TB-500 Peptide: What It Is, How It Works, and What the Research Shows

Longevity Peptides

DSIP Peptide: What It Is, How It Works, and What the Evidence Shows